Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000422521 | SCV000531869 | uncertain significance | not provided | 2018-08-08 | criteria provided, single submitter | clinical testing | A variant of uncertain significance has been identified in the ARFGEF2 gene. The c.955 G>A variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The c.955 G>A variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these population. Several in-silico splice prediction models predict that c.955 G>A creates a cryptic donor site which may supplant the natural donor site and lead to abnormal gene splicing. However, in the absence of RNA/functional studies, the actual effect of this sequence change in this individual is unknown. If this variant does not impact splicing, it will result in an E319K missense change. The E319K variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. However, this substitution occurs at a position that is not conserved. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |